Table 3 Disease activity at first and last study visit in children with PRD
From: Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
| Â | Study group A-M (GA-M) | Study group A (GA) | ||
|---|---|---|---|---|
| Â | First study visit | Last study visit | First study visit | Last study visit |
Disease activity parameters, median [IQR] | ||||
 CRP, mg/L (ref < 10) Missing, n (%) | 0.1 [0.1, 0.3] | 0.300 [0.1, 2.1] | 0.6 [0.3, 1.3] 1 (7.1) | 0.5 [0.3 1.0] 1 (7.1) |
 ESR, mm/h (ref < 15) Missing, n (%) | 6.0 [5.0, 7.0] 1 (7.1) | 5.0 [5.0, 7.0] 1 (7.1) | 4.0 [4.0, 6.0] 3 (21.4) | 7.0 [5.0, 8.0] 3 (21.4) |
 PGA, cm | 0.5 [0, 1.8] | 1.0 [0, 1.8] | 0 [0, 1.0] | 0 [0, 0] |
 PPGA, cm | 1.0 [0, 1.8] | 0.5 [0, 2.0] | 0 [0, 0] | 0 [0, 0] |
Disease activity in children with JIA (based on the JADAS-10), n (%) | ||||
|  | n = 12 | n = 8 | ||
 Inactive | 4 (33.3) | 4 (33.3) | 6 (75.0) | 7 (87.5) |
 Minimal | 4 (33.3) | 5 (41.7) | 1 (12.5) | 0 |
 Moderate | 2 (16.7) | 3 (25.0) | 1 (12.5) | 1 (12.5) |
 High | 1 (8.3) | 0 | 0 | 0 |
 Missing | 1 (8.3) | 0 | 0 | 0 |
Disease activity in children with uveitis (based on cells in field by SUN), n (%) | ||||
|  | n = 8 (n = 2 idiopathic uveitis, n = 6 JIA-uveitis) | n = 8 (n = 5 idiopathic uveitis, n = 3 JIA-uveitis) | ||
 Absent | 8 (100) | 5 (62.5) | 5 (62.5) | 7 (87.5) |
 Minimal | 0 | 2 (25.0) | 2 (25.0) | 0 |
 Mild | 0 | 0 | 1 (12.5) | 1 (12.5) |
 Missing | 0 | 1 (12.5) | 0 | 0 |